rs1154404 — ADH5 ADH5 Asthma Risk Haplotype Variant

ADH5 rs1154404 — The Hidden Regulator of Airway Nitric Oxide

Every breath you take depends on a delicate balance between molecules that keep bronchial smooth muscle relaxed and inflammatory signals that tighten it. S-nitrosoglutathione (GSNO)¹¹ S-nitrosoglutathione (GSNO)
GSNO is the predominant bioactive form of nitric oxide in airway lining fluid; it relaxes smooth muscle at nanomolar concentrations and is 100-fold more potent than the asthma drug theophylline as a bronchodilator is one of the lung's most powerful endogenous bronchodilators — and its concentration in the airways is controlled by a single enzyme, ADH5, officially known as S-nitrosoglutathione reductase (GSNOR). The rs1154404 variant sits in intron 1 of the ADH5 gene on chromosome 4 and serves as a proxy for nearby promoter variants that determine how much GSNOR the airways produce. The common A allele (plus-strand) tags a high-GSNOR-expression haplotype associated with elevated childhood asthma risk; the rarer T allele marks the protective low-expression end of the spectrum.

The Mechanism

GSNOR breaks down GSNO irreversibly, converting it to oxidized glutathione and ammonia. When GSNOR expression is elevated — as in the A-allele risk haplotype — airway GSNO levels fall, smooth muscle tone rises, and the lung loses its intrinsic bronchodilator reserve. This mechanism was confirmed directly in human lung: Que et al. 2009²² Que et al. 2009
GSNOR activity measured from BAL fluid in 13 asthmatic and 11 healthy adults; asthmatic samples showed GSNOR activity 1,223 vs 537 AU/mg protein found GSNOR activity more than doubled in asthmatic airways compared to healthy controls, while total S-nitrosothiol levels were halved. GSNOR activity correlated inversely with methacholine PC20 (r = 0.54, P = 0.008) — the tighter the enzyme grip on GSNO, the more hyperresponsive the airway.

rs1154404 itself is an intronic variant (intron 1 of ADH5) and does not change the GSNOR protein sequence. Its functional significance comes from being in near-complete linkage disequilibrium³³ near-complete linkage disequilibrium
LD r²=0.99, meaning this SNP almost always co-inherits with adjacent promoter variants across generations with two adjacent promoter SNPs — rs2602899 and rs2851301 — that sit within a putative NF-κB binding site⁴⁴ NF-κB binding site
NF-κB (nuclear factor kappa-B) is a master inflammatory transcription factor that, when active, drives expression of dozens of inflammation genes including GSNOR in the ADH5 promoter. The A allele is believed to preserve this NF-κB site intact, supporting higher GSNOR transcription in response to inflammatory signalling. The T allele disrupts the site, reducing GSNOR output and leaving more GSNO available as a bronchodilator.

ADH5 also clears formaldehyde — a ubiquitous environmental irritant from new furniture, pressed-wood building materials, and cigarette smoke — by metabolising the spontaneous formaldehyde-glutathione adduct S-hydroxymethylglutathione. When environmental formaldehyde load is high, it competes for the same enzyme capacity as GSNO, further depleting airway GSNO⁵⁵ further depleting airway GSNO
Thompson & Grafström 2008 — mechanistic analysis of how formaldehyde competes with GSNO for GSNOR enzyme capacity in the airway and potentially worsening bronchoconstriction — a dual-substrate competition that is most consequential in A-allele carriers whose GSNOR baseline is already elevated.

The Evidence

The primary genetic study by Wu et al. 2007⁶⁶ Wu et al. 2007
Journal of Allergy and Clinical Immunology; 532 nuclear families with asthmatic children aged 4–17, Mexico City; case-parent triad design removes population stratification enrolled 532 Mexican families with asthmatic children and genotyped seven GSNOR SNPs including rs1154404. Carrying one copy of the protective T allele was associated with a 23% reduced relative risk of asthma (RR 0.77, 95% CI 0.61–0.97, P = 0.028); carrying two copies reduced risk by 34% (RR 0.66, 95% CI 0.44–0.99, P = 0.046). Haplotype analysis confirmed the direction: the risk haplotype containing the A allele at rs1154404 carried RR 1.57 (P = 0.017) for asthma. Strikingly, these allele effects were not associated with degree of atopy (IgE levels, positive skin tests) — the GSNOR-GSNO axis affects airway smooth muscle tone independently of the classical IgE-mediated allergic cascade, pointing to a distinct non-atopic pathway to asthma susceptibility.

A 2017 review by Barnett & Buxton⁷⁷ Barnett & Buxton
Critical Reviews in Biochemistry and Molecular Biology; comprehensive synthesis of GSNOR biology and therapeutic targeting across multiple diseases validates the clinical significance: ADH5-null (knockout) mice show elevated airway S-nitrosothiol levels and are protected from allergen-induced airway hyperresponsiveness. This knockout phenotype — protective against asthma — is the molecular mirror image of what the A-allele risk haplotype produces in humans. The therapeutic direction is clear enough that GSNOR inhibitor N6022 entered Phase 2 clinical trials for asthma, with early signals of bronchial hyperreactivity improvement.

A pharmacogenomic layer emerges from Choudhry et al. 2010⁸⁸ Choudhry et al. 2010
The Pharmacogenomics Journal; 609 Latino asthmatic trios from the GALA cohort; functional cell transfection experiments confirmed risk haplotype gain-of-function for GSNOR expression: GSNOR risk alleles interact with the ADRB2 Arg16Gly variant (rs1042713) to impair bronchodilator response to albuterol. Combined GSNOR + ADRB2 multi-locus genotyping achieved 70% predictive value for lack of response to albuterol in status asthmaticus, a clinically actionable pharmacogenomic signal.

The primary limitation of current evidence is that the genetic association derives from a single study in a Latin American pediatric cohort, with replication in European or Asian populations still lacking. This keeps the evidence level at moderate despite a compelling functional mechanism and therapeutic confirmation.

Practical Actions

The rs1154404 A-allele risk haplotype operates through a mechanism distinct from allergic sensitisation: it impairs the airway's intrinsic bronchodilator reserve via GSNO depletion. This means conventional allergy management (antihistamines, IgE reduction) does not address the root issue. Interventions that restore airway nitric oxide availability — through dietary nitrate and GSNO-sparing strategies — are mechanistically targeted to this variant. Formaldehyde exposure is a uniquely relevant trigger because it competes directly for the enzyme whose overactivity the A allele drives, compounding the GSNO deficit.

Interactions

rs28730619 (also in ADH5) is the companion variant on the same asthma risk haplotype: the C allele at rs28730619 combined with the A allele here marks the highest-risk GSNOR haplotype identified in Wu et al. 2007. The two variants are partially in LD and the risk haplotype is defined by their co-inheritance.

The ADRB2 Arg16Gly variant (rs1042713) interacts with the GSNOR risk haplotype to predict bronchodilator response to albuterol — carriers of both risk configurations show the most impaired acute beta-agonist response. This gene-gene interaction is clinically actionable: combined GSNOR + ADRB2 genotyping explains approximately 70% of albuterol non-response in status asthmaticus in paediatric cohorts.